About: http://data.cimple.eu/news-article/9beaab7dfad3ceac61ecc917e0388cfb8be6635d2c1310bfaef5195e

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/9beaab7dfad3ceac61ecc917e0388cfb8be6635d2c1310bfaef5195e Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Brazil will begin advanced clinical testing of a Chinese-made vaccine against the new coronavirus Tuesday, issuing the first doses to around 900 volunteers, officials said. The coronavirus vaccine, developed by private Chinese pharmaceutical firm Sinovac, is the third in the world to enter Phase 3 trials, or large-scale testing on humans -- the last step before regulatory approval. It will be administered to doctors and other health workers who volunteer for the program across six states in Brazil, one of the countries hit hardest by the pandemic. "Trials of CoronaVac, one of the vaccines that has advanced furthest in testing in the world, will begin at the Clinical Hospital of Sao Paulo," the state's governor, Joao Doria, told a news conference. He said initial results were expected within 90 days. Sinovac is partnering with a Brazilian public health research center, the Butantan Institute, on the trials. If the vaccine proves safe and effective, the institute will have the right to produce 120 million doses under the deal, according to officials. "In Brazil, we could have the first vaccine to be put to widespread use, which is very, very promising," said the head of the Butantan Institute, Dimas Covas. Brazil is the second-hardest-hit country in the coronavirus pandemic, after the United States. Its death toll surpassed 80,000 on Monday, and it has registered 2.1 million infections. Those grim figures make it an ideal testing ground for potential vaccines, since the virus is still spreading quickly. Brazil is also helping carry out Phase 3 testing of another experimental vaccine, developed by Oxford University in Britain and pharmaceutical firm AstraZeneca. Another vaccine, developed by state-owned Chinese company Sinopharm, also entered Phase 3 trials this month in the United Arab Emirates. They are the three most advanced of the dozens of projects worldwide by scientists racing to develop and test a vaccine against the new virus. A fourth, existing vaccine against tuberculosis is also in Phase 3 trials in Australia as a potential coronavirus immunization. val/jhb/to
schema:headline	Brazil set to test Chinese coronavirus vaccine
schema:mentions	Instituto Butantan São Paulo Immunization 90 Days (film) Pharmaceutical industry Tuberculosis Sinovac Biotech Public health Ebola virus disease United Arab Emirates University of Oxford AstraZeneca Australia Pandemic Brazil Vaccine United States China Severe acute respiratory syndrome coronavirus 2 Tropical Storm Doria China National Pharmaceutical Group Valencia CF Church grim
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-07-21 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	75 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software